肝胆道系疾患治療薬ウルソデオキシコール酸の世界市場成長2024-2030年Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Growth 2024-2030 LPI(エルピーアイ情報)の最新調査によると、肝胆膵疾患向けウルソデオキシコール酸薬の世界市場規模は2023年に100万米ドルと評価されました。下流市場での需要の増加に伴い、肝胆道系疾患向けウルソデオキシコ... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリーLPI(エルピーアイ情報)の最新調査によると、肝胆膵疾患向けウルソデオキシコール酸薬の世界市場規模は2023年に100万米ドルと評価されました。下流市場での需要の増加に伴い、肝胆道系疾患向けウルソデオキシコール酸医薬品の市場規模は、レビュー期間中の年平均成長率(CAGR)%で2030年までに100万米ドルに再調整されると予測されています。この調査レポートは、世界の肝胆道疾患向けウルソデオキシコール酸薬市場の成長可能性を明らかにしています。肝胆道系疾患用ウルソデオキシコール酸薬は、今後の市場でも安定した成長が見込まれる。しかし、肝胆膵用ウルソデオキシコール酸製剤の普及には、製品の差別化、コスト削減、サプライチェーンの最適化が引き続き重要である。市場プレーヤーは、肝胆道系疾患用ウルソデオキシコール酸市場がもたらす大きなチャンスを活かすために、研究開発に投資し、戦略的パートナーシップを築き、進化する消費者の嗜好に合わせた製品を提供する必要がある。 ウルソデオキシコール酸は胆汁酸の一種で、原発性胆汁性肝硬変(PBC)の治療、胆嚢が機能していない患者における放射線透過性胆石の溶解、小児における嚢胞性線維症に伴う肝胆道系疾患の治療に使用される。 世界の医薬品市場は、2022年には1,475億ドルに達し、今後6年間のCAGRは5%で成長する。医薬品市場には、化学医薬品と生物学的製剤が含まれる。生物製剤は2022年に3810億ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造部門の開発に対する民間&政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要とする患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行はワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、製薬企業が公衆衛生の新たなニーズに機敏に対応する必要性をさらに強調している。 主な特徴 肝胆道系疾患用ウルソデオキシコール酸薬市場に関する本レポートは、様々な側面を反映し、業界に関する貴重な洞察を提供します。 市場規模と成長:この調査レポートは、肝胆道系疾患向けウルソデオキシコール酸薬市場の現在の規模と成長の概要を提供します。過去のデータ、タイプ別(カプセル、錠剤など)の市場細分化、地域別の内訳などが含まれます。 市場促進要因と課題:肝胆膵疾患向けウルソデオキシコール酸製剤市場の成長を促進する要因(政府規制、環境問題、技術進歩、消費者嗜好の変化など)を特定・分析することができます。また、インフラストラクチャーの制限、射程距離への不安、高額な初期費用など、業界が直面する課題も浮き彫りにすることができます。 競合情勢:当調査レポートでは、肝胆膵疾患向けウルソデオキシコール酸薬市場内の競合状況の分析を提供しています。主要企業のプロフィール、市場シェア、戦略、製品提供などが含まれています。また、新興プレーヤーとその市場に与える潜在的な影響にもスポットを当てています。 技術開発:本調査レポートでは、肝胆道疾患用ウルソデオキシコール酸製剤業界における最新の技術開発について掘り下げることができます。これには、肝胆膵疾患用ウルソデオキシコール酸製剤技術の進歩、肝胆膵疾患用ウルソデオキシコール酸製剤の新規参入、肝胆膵疾患用ウルソデオキシコール酸製剤の新規投資、肝胆膵疾患用ウルソデオキシコール酸製剤の将来を形作るその他のイノベーションなどが含まれます。 川下企業の好み:本レポートは、肝胆膵疾患用ウルソデオキシコール酸市場における顧客の購買行動や採用動向を明らかにします。顧客の購買決定や肝胆道系疾患用ウルソデオキシコール酸製剤の嗜好に影響を与える要因も含まれています。 政府の政策とインセンティブこの調査レポートは、肝胆膵用ウルソデオキシコール酸市場に対する政府の政策とインセンティブの影響を分析しています。これには、規制の枠組み、補助金、税制優遇措置、肝胆膵疾患向けウルソデオキシコール酸製剤市場の促進を目的としたその他の措置の評価が含まれます。また、これらの政策が市場成長を促進する効果についても評価しています。 環境への影響と持続可能性当調査レポートでは、肝胆膵疾患向けウルソデオキシコール酸薬市場の環境への影響と持続可能性の側面を評価しています。 市場予測と将来展望:当調査レポートでは、実施した分析に基づいて、肝胆道系疾患用ウルソデオキシコール酸製剤産業の市場予測と展望を提供しています。これには、市場規模、成長率、地域動向、技術進歩や政策展開に関する予測などが含まれます。 提言と機会:本レポートは、業界関係者、政策立案者、投資家への提言で締めくくられています。市場関係者が新たなトレンドを活用し、課題を克服し、肝胆道疾患用ウルソデオキシコール酸薬市場の成長と発展に貢献するための潜在的な機会を強調しています。 市場セグメンテーション 肝胆道系疾患向けウルソデオキシコール酸薬市場は、タイプ別と用途別に分けられます。2019年から2030年までの期間について、セグメント間の成長により、タイプ別、用途別の消費額の正確な計算と予測を数量と金額で提供します。 タイプ別セグメント カプセル剤 錠剤 用途別セグメント 原発性胆汁性肝硬変(PBC) 胆石症 その他 また、本レポートでは地域別に市場を分割しています: 南北アメリカ アメリカ カナダ メキシコ ブラジル APAC 中国 日本 韓国 東南アジア インド オーストラリア ヨーロッパ ドイツ フランス 英国 イタリア ロシア 中東・アフリカ エジプト 南アフリカ イスラエル トルコ GCC諸国 以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。 ファルク・ファーマ 大雄製薬 テバ ヒューマンウェル 田辺三菱製薬 ランネット マイラン ブルシェッティーニ インパックス 上海製薬 グリンデクス 本レポートで扱う主な質問 肝胆道疾患治療薬ウルソデオキシコール酸の世界市場10年見通しは? 肝胆道系疾患用ウルソデオキシコール酸製剤の世界市場および地域別市場成長を促進する要因は何か? 市場別、地域別で最も急成長する技術は何か? 肝胆道疾患用ウルソデオキシコール酸製剤の市場機会は最終市場規模によってどのように異なるのか? 肝胆道疾患用ウルソデオキシコール酸製剤のタイプ別、用途別内訳は? 目次1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Sales 2019-2030 2.1.2 World Current & Future Analysis for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Geographic Region, 2019, 2023 & 2030 2.1.3 World Current & Future Analysis for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Country/Region, 2019, 2023 & 2030 2.2 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Segment by Type 2.2.1 Capsule 2.2.2 Tablet 2.3 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type 2.3.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share by Type (2019-2024) 2.3.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue and Market Share by Type (2019-2024) 2.3.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sale Price by Type (2019-2024) 2.4 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Segment by Application 2.4.1 Primary Biliary Cirrhosis(PBC) 2.4.2 Gallstones 2.4.3 Others 2.5 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application 2.5.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sale Market Share by Application (2019-2024) 2.5.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue and Market Share by Application (2019-2024) 2.5.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sale Price by Application (2019-2024) 3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Company 3.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Breakdown Data by Company 3.1.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Sales by Company (2019-2024) 3.1.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share by Company (2019-2024) 3.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Revenue by Company (2019-2024) 3.2.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Company (2019-2024) 3.2.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share by Company (2019-2024) 3.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sale Price by Company 3.4 Key Manufacturers Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Location Distribution 3.4.2 Players Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) 3.6 New Products and Potential Entrants 3.7 Mergers & Acquisitions, Expansion 4 World Historic Review for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Geographic Region 4.1 World Historic Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size by Geographic Region (2019-2024) 4.1.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Sales by Geographic Region (2019-2024) 4.1.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Revenue by Geographic Region (2019-2024) 4.2 World Historic Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size by Country/Region (2019-2024) 4.2.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Sales by Country/Region (2019-2024) 4.2.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Revenue by Country/Region (2019-2024) 4.3 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Growth 4.4 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Growth 4.5 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Growth 4.6 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Growth 5 Americas 5.1 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Country 5.1.1 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Country (2019-2024) 5.1.2 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Country (2019-2024) 5.2 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type 5.3 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Region 6.1.1 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Region (2019-2024) 6.1.2 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Region (2019-2024) 6.2 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type 6.3 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Country 7.1.1 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Country (2019-2024) 7.1.2 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Country (2019-2024) 7.2 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type 7.3 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Country 8.1.1 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Country (2019-2024) 8.1.2 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Country (2019-2024) 8.2 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type 8.3 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases 10.3 Manufacturing Process Analysis of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases 10.4 Industry Chain Structure of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Distributors 11.3 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Customer 12 World Forecast Review for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Geographic Region 12.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size Forecast by Region 12.1.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Forecast by Region (2025-2030) 12.1.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Revenue Forecast by Region (2025-2030) 12.2 Americas Forecast by Country 12.3 APAC Forecast by Region 12.4 Europe Forecast by Country 12.5 Middle East & Africa Forecast by Country 12.6 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Forecast by Type 12.7 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Forecast by Application 13 Key Players Analysis 13.1 Dr. Falk Pharma 13.1.1 Dr. Falk Pharma Company Information 13.1.2 Dr. Falk Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.1.3 Dr. Falk Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.1.4 Dr. Falk Pharma Main Business Overview 13.1.5 Dr. Falk Pharma Latest Developments 13.2 Daewoong Pharmaceutical 13.2.1 Daewoong Pharmaceutical Company Information 13.2.2 Daewoong Pharmaceutical Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.2.3 Daewoong Pharmaceutical Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.2.4 Daewoong Pharmaceutical Main Business Overview 13.2.5 Daewoong Pharmaceutical Latest Developments 13.3 Teva 13.3.1 Teva Company Information 13.3.2 Teva Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.3.3 Teva Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.3.4 Teva Main Business Overview 13.3.5 Teva Latest Developments 13.4 Humanwell 13.4.1 Humanwell Company Information 13.4.2 Humanwell Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.4.3 Humanwell Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.4.4 Humanwell Main Business Overview 13.4.5 Humanwell Latest Developments 13.5 Mitsubishi Tanabe Pharma 13.5.1 Mitsubishi Tanabe Pharma Company Information 13.5.2 Mitsubishi Tanabe Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.5.3 Mitsubishi Tanabe Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.5.4 Mitsubishi Tanabe Pharma Main Business Overview 13.5.5 Mitsubishi Tanabe Pharma Latest Developments 13.6 Lannett 13.6.1 Lannett Company Information 13.6.2 Lannett Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.6.3 Lannett Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.6.4 Lannett Main Business Overview 13.6.5 Lannett Latest Developments 13.7 Mylan 13.7.1 Mylan Company Information 13.7.2 Mylan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.7.3 Mylan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.7.4 Mylan Main Business Overview 13.7.5 Mylan Latest Developments 13.8 Bruschettini 13.8.1 Bruschettini Company Information 13.8.2 Bruschettini Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.8.3 Bruschettini Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.8.4 Bruschettini Main Business Overview 13.8.5 Bruschettini Latest Developments 13.9 Impax 13.9.1 Impax Company Information 13.9.2 Impax Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.9.3 Impax Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.9.4 Impax Main Business Overview 13.9.5 Impax Latest Developments 13.10 Shanghai Pharma 13.10.1 Shanghai Pharma Company Information 13.10.2 Shanghai Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.10.3 Shanghai Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.10.4 Shanghai Pharma Main Business Overview 13.10.5 Shanghai Pharma Latest Developments 13.11 Grindeks 13.11.1 Grindeks Company Information 13.11.2 Grindeks Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.11.3 Grindeks Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.11.4 Grindeks Main Business Overview 13.11.5 Grindeks Latest Developments 14 Research Findings and Conclusion
SummaryAccording to our LPI (LP Information) latest study, the global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market size was valued at US$ million in 2023. With growing demand in downstream market, the Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. Table of Contents1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Sales 2019-2030 2.1.2 World Current & Future Analysis for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Geographic Region, 2019, 2023 & 2030 2.1.3 World Current & Future Analysis for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Country/Region, 2019, 2023 & 2030 2.2 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Segment by Type 2.2.1 Capsule 2.2.2 Tablet 2.3 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type 2.3.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share by Type (2019-2024) 2.3.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue and Market Share by Type (2019-2024) 2.3.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sale Price by Type (2019-2024) 2.4 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Segment by Application 2.4.1 Primary Biliary Cirrhosis(PBC) 2.4.2 Gallstones 2.4.3 Others 2.5 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application 2.5.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sale Market Share by Application (2019-2024) 2.5.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue and Market Share by Application (2019-2024) 2.5.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sale Price by Application (2019-2024) 3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Company 3.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Breakdown Data by Company 3.1.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Sales by Company (2019-2024) 3.1.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share by Company (2019-2024) 3.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Revenue by Company (2019-2024) 3.2.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Company (2019-2024) 3.2.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share by Company (2019-2024) 3.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sale Price by Company 3.4 Key Manufacturers Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Location Distribution 3.4.2 Players Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) 3.6 New Products and Potential Entrants 3.7 Mergers & Acquisitions, Expansion 4 World Historic Review for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Geographic Region 4.1 World Historic Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size by Geographic Region (2019-2024) 4.1.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Sales by Geographic Region (2019-2024) 4.1.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Revenue by Geographic Region (2019-2024) 4.2 World Historic Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size by Country/Region (2019-2024) 4.2.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Sales by Country/Region (2019-2024) 4.2.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Revenue by Country/Region (2019-2024) 4.3 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Growth 4.4 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Growth 4.5 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Growth 4.6 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Growth 5 Americas 5.1 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Country 5.1.1 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Country (2019-2024) 5.1.2 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Country (2019-2024) 5.2 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type 5.3 Americas Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Region 6.1.1 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Region (2019-2024) 6.1.2 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Region (2019-2024) 6.2 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type 6.3 APAC Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Country 7.1.1 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Country (2019-2024) 7.1.2 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Country (2019-2024) 7.2 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type 7.3 Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Country 8.1.1 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Country (2019-2024) 8.1.2 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Country (2019-2024) 8.2 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Type 8.3 Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases 10.3 Manufacturing Process Analysis of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases 10.4 Industry Chain Structure of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Distributors 11.3 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Customer 12 World Forecast Review for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases by Geographic Region 12.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size Forecast by Region 12.1.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Forecast by Region (2025-2030) 12.1.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Annual Revenue Forecast by Region (2025-2030) 12.2 Americas Forecast by Country 12.3 APAC Forecast by Region 12.4 Europe Forecast by Country 12.5 Middle East & Africa Forecast by Country 12.6 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Forecast by Type 12.7 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Forecast by Application 13 Key Players Analysis 13.1 Dr. Falk Pharma 13.1.1 Dr. Falk Pharma Company Information 13.1.2 Dr. Falk Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.1.3 Dr. Falk Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.1.4 Dr. Falk Pharma Main Business Overview 13.1.5 Dr. Falk Pharma Latest Developments 13.2 Daewoong Pharmaceutical 13.2.1 Daewoong Pharmaceutical Company Information 13.2.2 Daewoong Pharmaceutical Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.2.3 Daewoong Pharmaceutical Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.2.4 Daewoong Pharmaceutical Main Business Overview 13.2.5 Daewoong Pharmaceutical Latest Developments 13.3 Teva 13.3.1 Teva Company Information 13.3.2 Teva Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.3.3 Teva Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.3.4 Teva Main Business Overview 13.3.5 Teva Latest Developments 13.4 Humanwell 13.4.1 Humanwell Company Information 13.4.2 Humanwell Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.4.3 Humanwell Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.4.4 Humanwell Main Business Overview 13.4.5 Humanwell Latest Developments 13.5 Mitsubishi Tanabe Pharma 13.5.1 Mitsubishi Tanabe Pharma Company Information 13.5.2 Mitsubishi Tanabe Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.5.3 Mitsubishi Tanabe Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.5.4 Mitsubishi Tanabe Pharma Main Business Overview 13.5.5 Mitsubishi Tanabe Pharma Latest Developments 13.6 Lannett 13.6.1 Lannett Company Information 13.6.2 Lannett Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.6.3 Lannett Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.6.4 Lannett Main Business Overview 13.6.5 Lannett Latest Developments 13.7 Mylan 13.7.1 Mylan Company Information 13.7.2 Mylan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.7.3 Mylan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.7.4 Mylan Main Business Overview 13.7.5 Mylan Latest Developments 13.8 Bruschettini 13.8.1 Bruschettini Company Information 13.8.2 Bruschettini Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.8.3 Bruschettini Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.8.4 Bruschettini Main Business Overview 13.8.5 Bruschettini Latest Developments 13.9 Impax 13.9.1 Impax Company Information 13.9.2 Impax Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.9.3 Impax Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.9.4 Impax Main Business Overview 13.9.5 Impax Latest Developments 13.10 Shanghai Pharma 13.10.1 Shanghai Pharma Company Information 13.10.2 Shanghai Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.10.3 Shanghai Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.10.4 Shanghai Pharma Main Business Overview 13.10.5 Shanghai Pharma Latest Developments 13.11 Grindeks 13.11.1 Grindeks Company Information 13.11.2 Grindeks Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Portfolios and Specifications 13.11.3 Grindeks Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, Revenue, Price and Gross Margin (2019-2024) 13.11.4 Grindeks Main Business Overview 13.11.5 Grindeks Latest Developments 14 Research Findings and Conclusion
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医薬)の最新刊レポート
LP Information社の医薬品・ヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD(ursodeoxycholic)の最新刊レポートよくあるご質問LP Information社はどのような調査会社ですか?LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/21 10:26 156.13 円 165.08 円 200.38 円 |